These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 35179349)

  • 1. Depleting Tumor Infiltrating B Cells to Boost Antitumor Immunity with Tumor Immune-Microenvironment Reshaped Hybrid Nanocage.
    Guan L; Zhang Z; Gao T; Fu S; Mu W; Liang S; Liu Y; Chu Q; Fang Y; Liu Y; Zhang N
    ACS Nano; 2022 Mar; 16(3):4263-4277. PubMed ID: 35179349
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ibrutinib Inhibits BTK Signaling in Tumor-Infiltrated B Cells and Amplifies Antitumor Immunity by PD-1 Checkpoint Blockade for Metastatic Prostate Cancer.
    Deng G; He J; Huang Q; Li T; Huang Z; Gao S; Xu J; Wang T; Di J
    Cancers (Basel); 2023 Apr; 15(8):. PubMed ID: 37190284
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting Ibrutinib to Tumor-Infiltrating T Cells with a Sialic Acid Conjugate-Modified Phospholipid Complex for Improved Tumor Immunotherapy.
    Li C; Fan C; Lu S; Qiu Q; Gao X; Yan X; Wang S; Zhao B; Liu X; Song Y; Deng Y
    Mol Pharm; 2023 Jan; 20(1):438-450. PubMed ID: 36382950
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bruton's tyrosine kinase (BTK) as a promising target in solid tumors.
    Molina-Cerrillo J; Alonso-Gordoa T; Gajate P; Grande E
    Cancer Treat Rev; 2017 Jul; 58():41-50. PubMed ID: 28641100
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeted delivery of ibrutinib to tumor-associated macrophages by sialic acid-stearic acid conjugate modified nanocomplexes for cancer immunotherapy.
    Qiu Q; Li C; Song Y; Shi T; Luo X; Zhang H; Hu L; Yan X; Zheng H; Liu M; Liu M; Liu M; Yang S; Liu X; Chen G; Deng Y
    Acta Biomater; 2019 Jul; 92():184-195. PubMed ID: 31108259
    [TBL] [Abstract][Full Text] [Related]  

  • 6. pH-sensitive tumor-tropism hybrid membrane-coated nanoparticles for reprogramming the tumor microenvironment and boosting the antitumor immunity.
    Zhang J; Wei L; Ma X; Wang J; Liang S; Chen K; Wu M; Niu L; Zhang Y
    Acta Biomater; 2023 Aug; 166():470-484. PubMed ID: 37253416
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intratumoral immunoglobulin isotypes predict survival in lung adenocarcinoma subtypes.
    Isaeva OI; Sharonov GV; Serebrovskaya EO; Turchaninova MA; Zaretsky AR; Shugay M; Chudakov DM
    J Immunother Cancer; 2019 Oct; 7(1):279. PubMed ID: 31665076
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cancer-cell-secreted CXCL11 promoted CD8
    Gao Q; Wang S; Chen X; Cheng S; Zhang Z; Li F; Huang L; Yang Y; Zhou B; Yue D; Wang D; Cao L; Maimela NR; Zhang B; Yu J; Wang L; Zhang Y
    J Immunother Cancer; 2019 Feb; 7(1):42. PubMed ID: 30744691
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tumor infiltrating CD19
    Lin Z; Liu L; Xia Y; Chen X; Xiong Y; Qu Y; Wang J; Bai Q; Guo J; Xu J
    Oncoimmunology; 2018; 7(10):e1477461. PubMed ID: 30288343
    [TBL] [Abstract][Full Text] [Related]  

  • 10. TGF-β blockade-improved chemo-immunotherapy with pH/ROS cascade-responsive micelle via tumor microenvironment remodeling.
    Dai L; Li X; Zheng X; Fu Z; Yao M; Meng S; Zhang J; Han B; Gao Q; Chang J; Cai K; Yang H
    Biomaterials; 2021 Sep; 276():121010. PubMed ID: 34247042
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Injectable Liquid Crystal Formation System for Reshaping Tumor Immunosuppressive Microenvironment to Boost Antitumor Immunity: Postoperative Chemoimmunotherapy.
    Hu M; Zhang J; Yu Y; Tu K; Yang T; Wang Y; Hu Q; Kong L; Zhang Z
    Small; 2020 Dec; 16(50):e2004905. PubMed ID: 33206460
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Myeloid-Derived Suppressor Cells Express Bruton's Tyrosine Kinase and Can Be Depleted in Tumor-Bearing Hosts by Ibrutinib Treatment.
    Stiff A; Trikha P; Wesolowski R; Kendra K; Hsu V; Uppati S; McMichael E; Duggan M; Campbell A; Keller K; Landi I; Zhong Y; Dubovsky J; Howard JH; Yu L; Harrington B; Old M; Reiff S; Mace T; Tridandapani S; Muthusamy N; Caligiuri MA; Byrd JC; Carson WE
    Cancer Res; 2016 Apr; 76(8):2125-36. PubMed ID: 26880800
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Heterodimeric IL-15 delays tumor growth and promotes intratumoral CTL and dendritic cell accumulation by a cytokine network involving XCL1, IFN-γ, CXCL9 and CXCL10.
    Bergamaschi C; Pandit H; Nagy BA; Stellas D; Jensen SM; Bear J; Cam M; Valentin A; Fox BA; Felber BK; Pavlakis GN
    J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32461349
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Melittin-MIL-2 fusion protein as a candidate for cancer immunotherapy.
    Liu M; Wang H; Liu L; Wang B; Sun G
    J Transl Med; 2016 Jun; 14(1):155. PubMed ID: 27246873
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High-dose IL-2/CD25 fusion protein amplifies vaccine-induced CD4
    Hernandez R; LaPorte KM; Hsiung S; Santos Savio A; Malek TR
    J Immunother Cancer; 2021 Sep; 9(9):. PubMed ID: 34475132
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ATR inhibitor AZD6738 enhances the antitumor activity of radiotherapy and immune checkpoint inhibitors by potentiating the tumor immune microenvironment in hepatocellular carcinoma.
    Sheng H; Huang Y; Xiao Y; Zhu Z; Shen M; Zhou P; Guo Z; Wang J; Wang H; Dai W; Zhang W; Sun J; Cao C
    J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32461345
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dual-responsive nanosystem based on TGF-β blockade and immunogenic chemotherapy for effective chemoimmunotherapy.
    Huang X; Han L; Wang R; Zhu W; Zhang N; Qu W; Liu W; Liu F; Feng F; Xue J
    Drug Deliv; 2022 Dec; 29(1):1358-1369. PubMed ID: 35506467
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nanomicelle protects the immune activation effects of Paclitaxel and sensitizes tumors to anti-PD-1 Immunotherapy.
    Yang Q; Shi G; Chen X; Lin Y; Cheng L; Jiang Q; Yan X; Jiang M; Li Y; Zhang H; Wang H; Wang Y; Wang Q; Zhang Y; Liu Y; Su X; Dai L; Tang M; Li J; Zhang L; Qian Z; Yu D; Deng H
    Theranostics; 2020; 10(18):8382-8399. PubMed ID: 32724476
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Engineering Endogenous Tumor-Associated Macrophage-Targeted Biomimetic Nano-RBC to Reprogram Tumor Immunosuppressive Microenvironment for Enhanced Chemo-Immunotherapy.
    Wang Y; Yu J; Luo Z; Shi Q; Liu G; Wu F; Wang Z; Huang Y; Zhou D
    Adv Mater; 2021 Oct; 33(39):e2103497. PubMed ID: 34387375
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Charge-switchable nanoparticles enhance Cancer immunotherapy based on mitochondrial dynamic regulation and immunogenic cell death induction.
    Zhao M; Li J; Liu J; Xu M; Ji H; Wu S; Chen D; Hu H
    J Control Release; 2021 Jul; 335():320-332. PubMed ID: 34062192
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.